Literature DB >> 17619842

[Lipopolysaccharide-mediated regulation of interleukin-6 in cultured human detrusor smooth muscle cells].

J Neuhaus1, N Schlichting, A Oberbach, J-U Stolzenburg.   

Abstract

BACKGROUND: Interleukin-6 (IL-6) is a pleiotropic cytokine which shows elevated plasma and urine levels in cancer and inflammatory diseases of the urinary tract. The aim of the study is to define IL-6 target gene regulation in cultivated human detrusor smooth muscle cells. PATIENTS AND METHODS: The expression of IL-6 and IL-6R (gp80, gp130) was studied by confocal immunofluorescence, rtPCR and Western blotting. Lipopolysaccharide (LPS) stimulation experiments were conducted in smooth muscle cell cultures derived from bladder biopsies of four male tumor patients.
RESULTS: IL-6 and IL-6R expression was found in urothelium, lamina propria and detrusor cells. LPS stimulation evoked a time-dependent synthesis and/or release of IL-6, IL-6R and STAT3.
CONCLUSIONS: Our results favor the notion that IL-6 can stimulate various cells of the human urinary bladder. Both detrusor cells and urothelium can serve as a source of elevated IL-6 levels. Finding genes regulated by IL-6 could be of great value for new therapeutical approaches in cancer and chronic inflammation of the lower urinary tract.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17619842     DOI: 10.1007/s00120-007-1479-2

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  14 in total

1.  Human detrusor smooth muscle cells release interleukin-6, interleukin-8, and RANTES in response to proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha.

Authors:  Kirsten Bouchelouche; Susana Alvarez; Thomas Horn; Jorgen Nordling; Pierre Bouchelouche
Journal:  Urology       Date:  2006-01       Impact factor: 2.649

Review 2.  Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.

Authors:  Hideko Nakahara; Norihiro Nishimoto
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2006-12       Impact factor: 2.895

Review 3.  Interleukin-6 trans-signaling in inflammatory bowel disease.

Authors:  Keiichi Mitsuyama; Michio Sata; Stefan Rose-John
Journal:  Cytokine Growth Factor Rev       Date:  2006-10-12       Impact factor: 7.638

Review 4.  Inflammation and cancer: how hot is the link?

Authors:  Bharat B Aggarwal; Shishir Shishodia; Santosh K Sandur; Manoj K Pandey; Gautam Sethi
Journal:  Biochem Pharmacol       Date:  2006-08-04       Impact factor: 5.858

Review 5.  [Clinical benefits of anti-human IL-6 receptor antibody therapy].

Authors:  Norihiro Nishimoto
Journal:  Clin Calcium       Date:  2007-04

6.  Preliminary study on urinary cytokine levels in interstitial cystitis: does intravesical bacille Calmette-Guérin treat interstitial cystitis by altering the immune profile in the bladder?

Authors:  K M Peters; A C Diokno; B W Steinert
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

7.  Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.

Authors:  Sylvie Negrier; David Perol; Christine Menetrier-Caux; Bernard Escudier; Marc Pallardy; Alain Ravaud; Jean-Yves Douillard; Christine Chevreau; Christine Lasset; Jean-Yves Blay; Michel Pallardy
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

8.  Identification of a novel IL-6 isoform binding to the endogenous IL-6 receptor.

Authors:  Michel P Bihl; Karl Heinimann; Jochen J Rüdiger; Oliver Eickelberg; André P Perruchoud; Michael Tamm; Michael Roth
Journal:  Am J Respir Cell Mol Biol       Date:  2002-07       Impact factor: 6.914

9.  Bacterial lipopolysaccharide induces proliferation of IL-6-dependent plasmacytoma cells by MAPK pathway activation.

Authors:  Lanko Iankov; Ganka Atanasova; Maria Praskova; Silvia Kalenderova; Dragomir Petrov; Vanio Mitev; Ivan Mitov
Journal:  Immunobiology       Date:  2004       Impact factor: 3.144

10.  Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer.

Authors:  V Michalaki; K Syrigos; P Charles; J Waxman
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

View more
  6 in total

1.  [High fat diet-induced molecular and physiological dysfunction of the urinary bladder].

Authors:  A Oberbach; N Schlichting; M Heinrich; Y Kullnick; S Lehmann; V Adams; J-W Stolzenburg; J Neuhaus
Journal:  Urologe A       Date:  2014-12       Impact factor: 0.639

2.  Uropathogenic Escherichia coli-induced inflammation alters mouse urinary bladder contraction via an interleukin-6-activated inducible nitric oxide synthase-related pathway.

Authors:  Te I Weng; Hsiao Yi Wu; Pei Ying Lin; Shing Hwa Liu
Journal:  Infect Immun       Date:  2009-05-26       Impact factor: 3.441

3.  Role of chronic E. coli infection in the process of bladder cancer- an experimental study.

Authors:  Hala El-Mosalamy; Tarek M Salman; Abeer M Ashmawey; Nada Osama
Journal:  Infect Agent Cancer       Date:  2012-08-08       Impact factor: 2.965

4.  Increased expression of interleukin-6 family members and receptors in urinary bladder with cyclophosphamide-induced bladder inflammation in female rats.

Authors:  Beatrice M Girard; Bopaiah P Cheppudira; Susan E Malley; Kristin C Schutz; Victor May; Margaret A Vizzard
Journal:  Front Neurosci       Date:  2011-02-22       Impact factor: 4.677

5.  Cytokine effects on gap junction communication and connexin expression in human bladder smooth muscle cells and suburothelial myofibroblasts.

Authors:  Marco Heinrich; Andreas Oberbach; Nadine Schlichting; Jens-Uwe Stolzenburg; Jochen Neuhaus
Journal:  PLoS One       Date:  2011-06-02       Impact factor: 3.240

6.  Free fatty acid palmitate impairs the vitality and function of cultured human bladder smooth muscle cells.

Authors:  Andreas Oberbach; Nadine Schlichting; Marco Heinrich; Holger Till; Jens-Uwe Stolzenburg; Jochen Neuhaus
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.